Summary of Immunome FY Conference Call (November 11, 2025) Company Overview - **Company**: Immunome (NasdaqCM:IMNM) - **Focus**: Standalone pure-play cancer company specializing in targeted therapies, including antibody-based therapies, radioligands, and small molecules [1][1] Key Points on Varegacestat - **Asset**: Varegacestat, a gamma-secretase inhibitor, is nearing completion of phase three clinical trials for desmoid tumors [2][2] - **Market Opportunity**: The commercial opportunity in desmoid tumors is substantial, with approximately 1,650 new cases per year in the US and a prevalence of about 30,000 [9][15] - **Differentiation**: Varegacestat is expected to differentiate itself from Ogsivo (nirogacestat) due to better efficacy and dosing convenience (once daily vs. twice daily) [10][10][22][22] - **Phase 2 Data**: Phase 2 data indicated a significant improvement over nirogacestat, with a median tumor volume reduction that was 20-25% better [10][10] - **Regulatory Readiness**: The company is well-prepared for regulatory submission and product launch, with a strong team in place [14][14] Clinical Trial Insights - **Enrollment**: Enrollment for the phase 3 trial was completed in February 2024, with data expected to be released soon [11][11] - **Data Monitoring**: A Data Safety Monitoring Board (DSMB) has been overseeing the trial, ensuring safety and compliance [24][24] - **Comparison with Competitors**: The trial design and patient enrollment criteria are nearly identical to those used in SpringWorks' trial for nirogacestat, which is considered the gold standard [17][18] ADC Development - **ROR1 ADC**: Immunome is developing an antibody-drug conjugate (ADC) targeting ROR1, utilizing a proprietary payload (HC74) [27][27] - **Technology Differentiation**: The ADC aims to improve upon existing technologies by addressing common resistance pathways and enhancing permeability for better therapeutic activity [32][32][33][33] - **Future Pipeline**: The company plans to introduce additional ADCs in 2026 and 2027, with a focus on high internalization antibodies [34][34] Market Potential - **Revenue Potential**: A drug targeting 3,000 patients could generate over a billion dollars in revenue, with a significant number of treatable patients available in the US and Europe [15][15] - **Patient Compliance**: The once-daily dosing of Varegacestat is expected to improve patient compliance compared to competitors [10][10] Conclusion - Immunome is positioned to capitalize on the growing market for targeted cancer therapies, with a strong focus on developing innovative treatments that offer significant advantages over existing options. The upcoming data release for Varegacestat is highly anticipated and could be a pivotal moment for the company.

Core Insights - Immunome, Inc. is set to present at the 2nd Annual Guggenheim Healthcare Innovation Conference on November 11, 2025, at 8:30 a.m. ET [1] - The company focuses on developing first-in-class and best-in-class targeted cancer therapies, with a strong emphasis on innovative therapeutics [3] Company Overview - Immunome is a clinical-stage targeted oncology company dedicated to improving outcomes for cancer patients through advanced therapies [3] - The company has a diverse pipeline, including varegacestat in Phase 3 for desmoid tumors, IM-1021 in Phase 1 targeting ROR1, and IM-3050, a FAP-targeted radioligand that has received IND clearance [3] - Additional preclinical ADCs in the pipeline include IM-1617, IM-1335, and IM-1340, targeting undisclosed markers in various solid tumors [3] Recent Developments - Immunome recently presented preclinical data indicating that its proprietary ADC payload HC74 can overcome multiple mechanisms of ADC resistance, enhancing the efficacy of its therapies [5] - The company has granted inducement awards of stock options to new employees, totaling 69,000 shares on October 1, 2025, and 117,000 shares on September 2, 2025, under Nasdaq Listing Rule 5635(c)(4) [6][7]

Core Viewpoint - Immunome, Inc. is focused on developing innovative targeted cancer therapies and will present at the 2nd Annual Guggenheim Healthcare Innovation Conference on November 11, 2025 [1][2]. Company Overview - Immunome is a clinical-stage biotechnology company dedicated to creating first-in-class and best-in-class targeted therapies for cancer patients [3]. - The company has a portfolio that includes advanced pipeline programs such as varegacestat, IM-1021, and IM-3050, with various stages of clinical trials [3]. Pipeline and Research - The most advanced programs include: - Varegacestat (formerly AL102), a gamma secretase inhibitor in Phase 3 trials for desmoid tumors [3]. - IM-1021, a ROR1-targeted ADC currently in Phase 1 trials [3]. - IM-3050, a FAP-targeted radioligand that has recently received IND clearance [3]. - Immunome has also presented preclinical data indicating that its proprietary ADC payload HC74 can overcome multiple mechanisms of ADC resistance [5]. Inducement Grants - On October 1, 2025, Immunome granted inducement awards consisting of non-statutory stock options for 69,000 shares to five new employees [6]. - Additionally, on September 2, 2025, the company granted inducement awards for 117,000 shares to eight new employees [7].

Company Overview - Immunome, Inc. (IMNM) shares increased by 6.1% to close at $11.2, supported by higher trading volume compared to normal sessions [1] - The stock has gained 3.9% over the past four weeks [1] Pipeline and Development - The price surge is linked to growing investor optimism regarding the development of varegacestat, the company's lead pipeline candidate, currently in late-stage studies for treating desmoid tumors [2] - Immunome is also working on other targeted therapies in early-stage studies for various cancer indications [2] Financial Expectations - The company is projected to report a quarterly loss of $0.57 per share, reflecting a year-over-year increase of 26.9% [3] - Expected revenues are $2.93 million, which is a 0.7% increase from the same quarter last year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating a lack of earnings estimate revisions [4] Industry Context - Immunome operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Precision BioSciences (DTIL) [4] - Precision BioSciences' consensus EPS estimate has also remained unchanged at -$0.31, showing a year-over-year change of 89.1% [5]

Core Insights - Immunome, Inc. (IMNM) shares increased by 6% to close at $9.3, driven by higher trading volume compared to typical sessions, contrasting with a 0.1% gain over the past four weeks [1][2] Company Performance - The rise in stock price is linked to growing investor optimism regarding the development of varegacestat, which is in late-stage clinical studies for treating desmoid tumors, alongside other early-stage cancer therapies [2] - The company is projected to report a quarterly loss of $0.52 per share, reflecting a year-over-year decline of 6.1%, with expected revenues of $2.47 million, an increase of 4.5% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 1.9% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Immunome is categorized under the Zacks Medical - Biomedical and Genetics industry, where Nurix Therapeutics, Inc. (NRIX) also operates, closing 2.2% lower at $11.39, with a 9.5% return over the past month [5] - Nurix Therapeutics has an unchanged consensus EPS estimate of -$0.72 for the upcoming report, representing a year-over-year change of -1.4% [6]